GB
Therapeutic Areas
Oramed Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ORMD-0801 | Type 2 Diabetes | Phase 3 |
| ORMD-0901 | Type 2 Diabetes / Obesity | Pre-clinical / Phase 1 |
| Oral Exenatide | Type 2 Diabetes | Phase 2 |
| Oral COVID-19 Vaccine | Prevention of COVID-19 | Pre-clinical |
Leadership Team at Oramed Pharmaceuticals
NK
Nadav Kidron
Chief Executive Officer and Director
DS
David Silberman
Chief Financial Officer
MK
Miriam Kidron
Chief Scientific Officer
JH
Joshua Hexter
Chief Operating Officer and Executive Vice President
MR
Michael Rabinowitz
General Counsel and Corporate Secretary
AF
Aviad Friedman
Vice President, Clinical Operations
LS
Leonard Sank
Chairman of the Board
BL
Brian L. Perlman
Director
KR
Kevin Rakin
Director
ZS
Zvi Shaked
Scientific Advisory Board